MyeloRx LLC
The Triptolide Company ™
Your Subtitle text


The Company is advised by a number of highly experienced scientific and business consultants.

Michael Andreeff, M.D., Ph.D.

Dr. Michael Andreeff received his M.D. and Ph.D. degrees from the University of Heidelberg in Germany and additional training and faculty appointments at Memorial Sloan-Kettering Cancer Center in the Departments of Pathology and Leukemia.  He has been a pioneer in flow cytometry since 1971, when he established the first flow cytometry laboratory at the University of Heidelberg and organized the first European conference on flow cytometry. In 1977, he joined Memorial Sloan-Kettering Cancer Center as head of the Leukemia Cell Biology and Hematopathology flow cytometry laboratory. He is currently a professor of medicine and holds the Paul and Mary Haas Chair in Genetics at MD Anderson. He has authored more than 450 published peer-reviewed papers, 5 books, and 75 book chapters.

He and his group have worked extensively on drug resistance in hematopoietic malignancies and breast cancer and developed or co-developed several new therapeutic agents, including the novel triterpenoids CDDO and CDDO-Me and Bcl-2, XIAP, survivin, MEK, and HDM2 inhibitors. He has published a number of papers on the utility of triptolide in models of AML.

Adil Daud, M.D.

Dr. Adil Daud, Director of Melanoma Clinical Research and Director of the Melanoma Program at the University of California, San Francisco (UCSF), is a specialist in melanoma and other skin cancers. In addition to caring for patients, he directs melanoma research to better understand the biology of melanoma and to develop new treatments for the disease. He has developed and led numerous early phase and melanoma specific clinical trials that have expanded the use of gene therapy for melanoma.

Dr. Daud earned a medical degree at the Government Medical College in Nagpur, India. He completed an internship and residency in internal medicine at Indiana University Medical Center, followed by a fellowship in hematology-oncology at Memorial Sloan-Kettering Cancer Center. Prior to joining UCSF Medical Center, he was a researcher at the Moffitt Cancer Center in Tampa, Fla. for seven years. Dr. Daud has won numerous awards, including the American Society for Clinical Oncology's Young Investigator award and Castle Connolly's Best Doctors in America award. He is an HS Clinical Professor of Medicine at UCSF.

Ann Welton, Ph.D.

Dr. Welton was a senior level pharmaceutical company executive leader in drug discovery research and early development for over 30 years before retiring in 2010. She has worked in multidisciplinary R&D environments in both large multinational pharmaceutical and biotechnology companies. From 1977 to 1997 she held leadership positions at Hoffmann LaRoche in Nutley, N.J. in Inflammation and Respiratory drug discovery research which culminated in her roles as Vice-President of Bronchopulmonary Research (1992-1994) and Vice-President of Nonclinical Development (1994-1997). From 1998 to 2003, Dr. Welton was Vice-President of Biology and Preclinical Development at the biotechnology company, Axys Pharmaceuticals (which in 2002 was acquired by Celera). From 2003 to 2010 Dr. Welton was Compound Development Team Leader for Immunology early development projects at the Johnson & Johnson Research Center in La Jolla, CA.  Dr. Welton received her Ph.D. in Biochemistry from Michigan State University and was a post-doctoral fellow at NIH in the Laboratory of the Nobel Laureate, Dr. Martin Rodbell, prior to joining the pharmaceutical industry.

Margaret (Peg) A. Horn, J.D.

Ms. Horn has over 25 years of experience in the pharmaceutical and biotechnology industries with an emphasis on transactions (including licensing, product acquisitions and divestitures, M&A) and intellectual property related matters.  Most recently she is the founder of Transact Business Consulting LLC and Chief Operating Officer of ProLynx LLC. Prior to founding Transact she was SVP, Corporate Development and General Counsel at Cogentus Pharmaceuticals and at Kosan Biosciences, Inc (KOSN).  Ms. Horn began her biotech career at Genencor International (GCOR) where she served in several capacities between 1991 and 2005, initially as patent counsel and finally as Senior Vice President of Legal and General Counsel. She began her career counseling the pharmaceutical division of E.I. du Pont de Nemours & Company.